CN1080529A - The manufacture method of dysentery medicine (Salibao) - Google Patents
The manufacture method of dysentery medicine (Salibao) Download PDFInfo
- Publication number
- CN1080529A CN1080529A CN 92106266 CN92106266A CN1080529A CN 1080529 A CN1080529 A CN 1080529A CN 92106266 CN92106266 CN 92106266 CN 92106266 A CN92106266 A CN 92106266A CN 1080529 A CN1080529 A CN 1080529A
- Authority
- CN
- China
- Prior art keywords
- rifampicin
- adjuvant
- salibao
- manufacture method
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- 208000001848 dysentery Diseases 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001482 bismuth subnitrate Drugs 0.000 claims abstract description 12
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract description 12
- 229960001225 rifampicin Drugs 0.000 claims abstract description 12
- 239000002671 adjuvant Substances 0.000 claims abstract description 9
- 238000010348 incorporation Methods 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 abstract description 6
- 244000144977 poultry Species 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 230000002458 infectious effect Effects 0.000 abstract description 4
- 238000012856 packing Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 239000000273 veterinary drug Substances 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of production veterinary drug---the manufacture method of dysentery medicine (Salibao), its prescription is: rifampicin, bismuth subnitrate and adjuvant; Process is: (1) dry, pulverize, sieve, and mix main materials and auxiliary materials in proportion (2), and (3) start mixer, fully mix in mixer, and incorporation time is not less than 30 minutes, (4) packing.Owing to also there is not a kind of specific drug that can treat the poultry infectious intestinal disease at present, therefore the medicine made from the present invention has been filled up this blank, and it can effectively suppress the intestinal disease of poultry, promotes the development of beastly fowl industry.
Description
The present invention relates to a kind of production method of veterinary drug, particularly treat the production method of the veterinary drug of poultry intestinal disease.
Hakuri and enteritis are the main infectious intestinal disease of poultry, and its pathogen is Salmonella, staphylococcus aureus etc.Above-mentioned disease propagation is strong, and the case fatality rate height already develops for beastly fowl to bring with social economy to have a strong impact on.Still there is not at present a kind of this sick veterinary drug for the treatment of.
The manufacture method that the purpose of this invention is to provide a kind of veterinary drug-dysentery medicine (Salibao), this veterinary drug can be treated the infectious intestinal disease of poultry.
Technical scheme of the present invention is:
1, the prescription of dysentery medicine (Salibao)
Rifampicin: bismuth subnitrate: adjuvant=1: 1.3-1.4: 6.5-6.6
2, foundation
Rifampicin is a broad ectrum antibiotic, and Gram-positive and negative bacterium are had stronger inhibition and bactericidal action, and parasites such as protozoon are also had certain lethal effect, and for example the MIC to golden yellow Fructus Vitis viniferae ball is 0.005 μ g/ml, and escherichia coli MIC is 2.5 μ g/ml; Bismuth subnitrate is widely used convergence medicine clinically, has the protection intestinal mucosa and avoids acids and stimulate, and makes enterokinesia miopragia and reaches anti-diarrhea effect, and have no side effect.
So rifampicin is cooperated the composition compound preparation in the proper ratio with bismuth subnitrate, make it to become existing antibacterial action, the treatment of astriction is arranged again and prevent the efficient medicine of enteritis, dysentery, it is possible that this medicine is used for beastly fowl.
3, technical process
(1), with adjuvant drying, pulverizing, cross 80 mesh sieves, weighing is standby;
(2), get rifampicin and bismuth subnitrate in proportion;
(3), start mixer, as ready become a full member normal after, with rifampicin, bismuth subnitrate and adjuvant with doubly measuring increase method mixing in mixer;
(4), incorporation time was greater than 30 minutes;
(5), packing.
Owing to also there is not a kind of specific drug for the treatment of the poultry infectious intestinal disease at present, therefore the medicine made from the present invention has been filled up this blank, has promoted the development of beastly fowl industry.
Provide an embodiment below.
1, prescription: rifampicin 112.5g
Bismuth subnitrate 150.0g
Glucose 737.5g
2, technical process
(1), with glucose drying, pulverizing, cross 80 mesh sieves;
(2), take by weighing rifampicin and bismuth subnitrate;
(3), start mixer, as ready become a full member normal after, rifampicin, bismuth subnitrate and glucose with doubly measuring the increase method, are mixed in mixer, incorporation time is 45 minutes, makes dysentery medicine (Salibao);
(4), packing, dysentery medicine (Salibao) is packed in the 10g plastic-aluminum pocket.
3, technological requirement
(1), supplementary material all should pass through 80 mesh sieves;
(2), supplementary material forbids to contact starch bowl;
(3), content uniformity is pressed powder, powder is stipulated less than ± 3%.
In adjuvant, also available calcium carbonate replaces glucose.
Claims (2)
1, a kind of manufacture method of veterinary drug-dysentery medicine (Salibao) is characterized in that:
(1), prescription rifampicin: bismuth subnitrate: adjuvant=1: 1.3-1.4: 6.5-6.6
(2), technical process
A, with adjuvant drying, pulverizing, cross 80 mesh sieves, weighing is standby;
B, get rifampicin and bismuth subnitrate in proportion;
C, start mixer, as ready become a full member normal after, with rifampicin, bismuth subnitrate and adjuvant with doubly measuring increase method mixing in mixer;
D, incorporation time were greater than 30 minutes.
2, manufacture method according to claim 1 is characterized in that: described adjuvant is glucose or calcium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 92106266 CN1080529A (en) | 1992-06-23 | 1992-06-23 | The manufacture method of dysentery medicine (Salibao) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 92106266 CN1080529A (en) | 1992-06-23 | 1992-06-23 | The manufacture method of dysentery medicine (Salibao) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1080529A true CN1080529A (en) | 1994-01-12 |
Family
ID=4941957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 92106266 Pending CN1080529A (en) | 1992-06-23 | 1992-06-23 | The manufacture method of dysentery medicine (Salibao) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1080529A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2292884A (en) * | 1994-09-12 | 1996-03-13 | Orion Yhtymae Oy | Rifamycin & bismuth salts for treating bacterial infections |
| GB2293323A (en) * | 1994-09-12 | 1996-03-27 | Orion Yhtymae Oy | Antibiotics and bismuth salts for treating bacterial infections |
-
1992
- 1992-06-23 CN CN 92106266 patent/CN1080529A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2292884A (en) * | 1994-09-12 | 1996-03-13 | Orion Yhtymae Oy | Rifamycin & bismuth salts for treating bacterial infections |
| GB2293323A (en) * | 1994-09-12 | 1996-03-27 | Orion Yhtymae Oy | Antibiotics and bismuth salts for treating bacterial infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69528204T2 (en) | Tablets containing amoxicillin and clavulanates, which are coated with a polymer | |
| DE2950977C2 (en) | ||
| DE2332484C2 (en) | Drugs with delayed release of active substances | |
| DE69110969T2 (en) | Use of triclosan for the treatment of diseases of the gastrointestinal tract. | |
| DE69715259T3 (en) | INTRAMIC VETERINARY MEDICINAL PRODUCT WITHOUT ANTI-INFECTIOUS ACTIVE SUBSTANCES | |
| DE3874917T2 (en) | COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH. | |
| EP0096286A2 (en) | Storage-stable tablets containing a hydrolysis-sensitive active agent | |
| DE3040780A1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES AND METHOD FOR THE PRODUCTION THEREOF | |
| EP0655249B1 (en) | Moenomycin as a medicament for the treatment of stomach ulcer | |
| DE19709897A1 (en) | Bismuth salts of antibiotics of the moenomycin group, process for their preparation, their use and medicaments containing such salts | |
| CN1080529A (en) | The manufacture method of dysentery medicine (Salibao) | |
| CN1057003A (en) | Medicinal feed for systemic treatment of fish ectoparasitic and ectobacterial diseases | |
| DE69125940T2 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 5-DIFLUORMETHOXY-2- [3,4-DIMETHOXY-2-PYRIDYL) METHYLSULFINYL] -1H-BENZIMIDAZOLE AND AN ANTI-HELIOBACTER AGENT FOR THE TREATMENT OF MAGNETIC DISEASES | |
| EP0749304B9 (en) | Slow-release tablet containing diclofenac-na | |
| US2638433A (en) | Pharmaceutical preparation for peptic ulcers | |
| EP0399479A1 (en) | Chewing gum for the disinfection of the mouth and the throat and process for its preparation | |
| DE854245C (en) | Process for the preparation of agents for inactivating proteolytic enzymes in the digestive tract | |
| US5707653A (en) | Ulcer treating composition comprising sufalcrate and antibiotic | |
| DE2715384B2 (en) | Medicines for diarrhea | |
| CN1028485C (en) | Preparation method of compound cydiodine buccal tablet | |
| DE69004941T2 (en) | Drug formulations to increase the effectiveness of beta-lactam antibiotics in prophylaxis and treatment of infectious disease due to pathogenic bacteria. | |
| CN1353933A (en) | Medicine for silkworm and its preparation method | |
| DE4129874C1 (en) | Granulating humic acids and/or cpds. - by mixing with granulating fluid for wet or moist granulation, then pressing through matrix | |
| KR20030021298A (en) | The composition of immune enhancer and intestinal regulator for animal | |
| KR920017653A (en) | Antitumor Compositions Containing Flunarizine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |